Your session is about to expire
← Back to Search
Pulmozyme for Coronavirus Disease
Phase 2
Waitlist Available
Research Sponsored by Boston Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
Study Summary
This trial is designed to study whether the use of Pulmozyme can improve clinical outcomes in patients with severe COVID-19 pneumonia who require mechanical ventilation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Ventilator-free days at 28 days
Secondary outcome measures
change in airway resistance
change in lung compliance
length of stay (ICU and hospital)
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Study DrugExperimental Treatment1 Intervention
Study drug
Group II: PlaceboPlacebo Group1 Intervention
Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pulmozyme
2005
Completed Phase 4
~20
Find a Location
Who is running the clinical trial?
South Shore HospitalOTHER
12 Previous Clinical Trials
10,781 Total Patients Enrolled
Boston Children's HospitalLead Sponsor
761 Previous Clinical Trials
5,579,870 Total Patients Enrolled
Brigham and Women's HospitalOTHER
1,616 Previous Clinical Trials
11,470,888 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger